MeSH term
Frequency | Condition_Probility | DNA Damage | 13 | 1.0 |
*DNA Repair | 2 | 0.0 |
Humans | 60 | 0.0 |
Models, Biological | 5 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 21 | 0.0 |
*Cell Cycle Proteins | 4 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
*DNA-Binding Proteins | 6 | 0.0 |
Gamma Rays | 3 | 1.0 |
Hydroxyurea/pharmacology | 3 | 5.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Phosphorylation | 16 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Animals | 25 | 0.0 |
Female | 15 | 0.0 |
Male | 14 | 0.0 |
Pregnancy | 2 | 0.0 |
Rats | 3 | 0.0 |
Blotting, Western | 4 | 0.0 |
*DNA Damage | 7 | 1.0 |
Enzyme Activation | 2 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Signal Transduction | 3 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Base Sequence | 6 | 0.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
DNA Repair | 7 | 1.0 |
DNA Replication | 2 | 0.0 |
K562 Cells | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
DNA Repair/*genetics | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Frameshift Mutation | 2 | 1.0 |
Phenotype | 4 | 0.0 |
*Protein-Serine-Threonine Kinases | 10 | 1.0 |
Amino Acid Sequence | 5 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Mice | 13 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Mutagenesis | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Aged | 2 | 0.0 |
Angiotensinogen/*genetics | 2 | 2.0 |
Genotype | 4 | 0.0 |
Middle Aged | 6 | 0.0 |
Hela Cells | 6 | 0.0 |
Radiation, Ionizing | 2 | 1.0 |
Adult | 5 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 3 | 2.0 |
Cell Line | 11 | 0.0 |
Down-Regulation | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 3 | 1.0 |
Chromatin/*metabolism | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Protein Kinases/metabolism | 5 | 1.0 |
*Xenopus Proteins | 3 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Serine/metabolism | 4 | 1.0 |
*Signal Transduction | 2 | 0.0 |
Mutation | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 2 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Syndrome | 2 | 0.0 |
Acetylation | 2 | 0.0 |
English Abstract | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Alleles | 4 | 0.0 |
Apoptosis | 2 | 0.0 |
Cells, Cultured | 4 | 0.0 |
Heterozygote | 2 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Nocodazole/pharmacology | 2 | 1.0 |
Protein p53/metabolism | 3 | 0.0 |
Time Factors | 5 | 0.0 |
Ultraviolet Rays | 5 | 0.0 |
Caffeine/pharmacology | 3 | 3.0 |
Comparative Study | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 2 | 4.0 |
Cell Division/drug effects | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Receptors, Angiotensin/*genetics | 2 | 4.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Cell Cycle | 6 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Renin-Angiotensin System/*genetics | 2 | 4.0 |
G2 Phase | 5 | 3.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Mitosis | 3 | 0.0 |
Transfection | 3 | 0.0 |
*Cell Cycle | 2 | 0.0 |
Cell Cycle Proteins | 2 | 11.0 |
DNA/metabolism | 2 | 0.0 |
Fibroblasts/metabolism | 3 | 0.0 |
S Phase | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Transcortin/*genetics | 2 | 40.0 |
alpha 1-Antitrypsin/*genetics | 3 | 11.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
*DNA Replication | 2 | 0.0 |
*Mutation | 3 | 0.0 |
Exons | 3 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
